<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577587</url>
  </required_header>
  <id_info>
    <org_study_id>EWK-002</org_study_id>
    <nct_id>NCT03577587</nct_id>
  </id_info>
  <brief_title>Efficacy of Herbal Galactagogue Silitidil After Preterm Birth</brief_title>
  <official_title>Effect and Efficacy of the Herbal Galactagogue Silitidil From Milk Thistle in Mothers of Very Preterm Newborns</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Waldkrankenhaus Protestant Hospital, Spandau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DMK Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Waldkrankenhaus Protestant Hospital, Spandau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After preterm birth mothers often suffer from hypogalactia. Herbal galactogogues can be used
      in order to increase milk production. In this double-blind, randomized, placebo-controlled
      clinical trial the effect of Silitidil, an extract from milk thistle, on the postpartal milk
      production in mothers of very premature newborns is investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mothers of preterm infants born at a gestational age &lt;= 32 wg are asked to participate in
      this double-blind, randomized, placebo-controlled interventional trial, where they will
      receive a preparation of the herbal galactogogue Silitidil or placebo over an intervention
      period of 3 weeks. The influence of the galactagogue will be investigated by monitoring daily
      milk production before, during and 1 week after cessation of the intervention. As secondary
      outcome parameters weight gain, the progress of enteral feeding, and the percentage of human
      milk feeding on total enteral feeding volumes will be monitored in the newborn infants. Also
      the breast milk composition (in terms of fatty acids, protein and carbohydrates content) will
      be investigated and compared between study groups. Saliva and urine probes will be collected
      at specific time points to survey hormonal reactions during the various phases of lactation
      and the relation of maternal hormone levels on milk production.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily milk production (ml/24h) at end of Intervention period</measure>
    <time_frame>3 weeks after study initiation</time_frame>
    <description>Daily milk production (ml/24h) according to pumping protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentual increase in daily milk production</measure>
    <time_frame>from 0 to 3 weeks after study initiation</time_frame>
    <description>Percentual increase in daily milk production comparing daily milk production (ml/24h) before and at end of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentual increase in daily milk production</measure>
    <time_frame>from 0 to 4 weeks after study initiation</time_frame>
    <description>Percentual increase in daily milk production comparing daily milk production (ml/24h) before and 1 week after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Milk Protein Content during intervention</measure>
    <time_frame>at 1 week after study initiation</time_frame>
    <description>Protein content in breast milk sample (mg/100ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Milk Protein Content at end of intervention</measure>
    <time_frame>at 3 weeks after study initiation</time_frame>
    <description>Protein content in breast milk sample (mg/100ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Milk Protein Content after intervention</measure>
    <time_frame>at 4 weeks after study initiation</time_frame>
    <description>Protein content in breast milk sample (mg/100ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Milk lactose Content during intervention</measure>
    <time_frame>at 1 week after study initiation</time_frame>
    <description>Lactose content in breast milk sample (mg/100ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Milk lactose Content at end of intervention</measure>
    <time_frame>at 3 weeks after study initiation</time_frame>
    <description>Lactose content in breast milk sample (mg/100ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Milk lactose Content after intervention</measure>
    <time_frame>at 4 weeks after study initiation</time_frame>
    <description>Lactose content in breast milk sample (mg/100ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Milk fatty acids Content during intervention</measure>
    <time_frame>at 1week after study initiation</time_frame>
    <description>Fatty acids content in breast milk sample (mg/100ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Milk fatty acids Content at end of intervention</measure>
    <time_frame>at 3 weeks after study initiation</time_frame>
    <description>Fatty acids content in breast milk sample (mg/100ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Milk fatty acids Content after intervention</measure>
    <time_frame>at 4 weeks after study initiation</time_frame>
    <description>Fatty acids content in breast milk sample (mg/100ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of formula feeding</measure>
    <time_frame>4 weeks</time_frame>
    <description>Incidence of (additional) formula feeding at 4 weeks of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time point when enteral feeding volumes reach 120 ml/kgbw</measure>
    <time_frame>4 weeks</time_frame>
    <description>day of life when enteral feeding volumes of the preterm Infant have reached 120 ml per kg bodyweight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of human milk feeding</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percentage of human milk feeding on total feeding volume of the preterm infant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily milk production (ml/24h), baseline</measure>
    <time_frame>at 0, 1 and 2 weeks after study initiation</time_frame>
    <description>Daily milk production (ml/24h) according to pumping protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily milk production (ml/24h), follow-up</measure>
    <time_frame>4 weeks after study initiation</time_frame>
    <description>Daily milk production (ml/24h) according to pumping protocol</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Maternal urine oxytocin/creatinin-ratio</measure>
    <time_frame>4 weeks</time_frame>
    <description>Maternal urine oxytocin and creatinin levels before and after breast pumping are determined to create oxytocin/creatin-ratio</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal Urine prolactin/creatinin-ratio</measure>
    <time_frame>4 weeks</time_frame>
    <description>Maternal urine prolactin and creatinin levels before and after breast pumping are determined to create prolactin/creatin-ratio</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal alpha-Amylase level in saliva</measure>
    <time_frame>4 weeks</time_frame>
    <description>Maternal alpha-amylase levels before and after breast pumping are determined in saliva samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Maternal cortisol level in saliva</measure>
    <time_frame>4 weeks</time_frame>
    <description>Maternal cortisol levels before and after breast pumping are determined in saliva samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of mastitis</measure>
    <time_frame>4 weeks</time_frame>
    <description>Incidence of clinical mastitis during intervention period</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Breast Milk Production</condition>
  <condition>Human Milk Feeding</condition>
  <condition>Hypogalactia</condition>
  <condition>Preterm Infant Nutrition</condition>
  <arm_group>
    <arm_group_label>Verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Silitidil for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-randomized healthy volunteering mothers after term birth receiving no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Silitidil for 21 days</intervention_name>
    <description>daily ingestion of herbal galactagogue Silitidil over time period of 3 weeks</description>
    <arm_group_label>Verum</arm_group_label>
    <other_name>Silitidil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo for 21 days</intervention_name>
    <description>daily ingestion of Placebo preparation over time period of 3 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mothers after preterm birth &lt;= 32 weeks of gestation

          -  Age of the newborn 1 - 5 days

          -  Human milk feeding intended

        Exclusion Criteria:

          -  Ingestion of other galactagogues

          -  maternal chronical disease requiring therapy (e.g. severe hypothyreosis, preexistent
             arterial hypertension, Type I or 2 Diabetes, chronic inflammatory bowel disease,
             severe bronchial asthma, pollinosis)

          -  medication influencing prolactine levels

          -  Mastitis at time of enrollment

          -  mammary tumors or surgery influencing milk production
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Jochum, MD</last_name>
    <role>Study Director</role>
    <affiliation>Head of Paediatric Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonia Nomayo, MD</last_name>
    <phone>0049 30 3702</phone>
    <phone_ext>2025</phone_ext>
    <email>antonia.nomayo@pgdiakonie.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank Jochum, MD</last_name>
    <phone>0049 30 3702</phone>
    <phone_ext>1022</phone_ext>
    <email>frank.jochum@pgdiakonie.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Evangelic Waldkrankenhaus Spandau, Paul Gerhardt Diakonie</name>
      <address>
        <city>Berlin-Spandau</city>
        <zip>13589</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonia Nomayo, MD</last_name>
      <phone>0049 30 3702</phone>
      <phone_ext>2025</phone_ext>
      <email>antonia.nomayo@pgdiakonie.de</email>
    </contact>
    <contact_backup>
      <last_name>Frank Jochum, MD</last_name>
      <phone>0049 30 3702</phone>
      <phone_ext>1022</phone_ext>
      <email>frank.jochum@pgdiakonie.de</email>
    </contact_backup>
    <investigator>
      <last_name>Antonia Nomayo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanna Petersen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Titus Sabi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Waldkrankenhaus Protestant Hospital, Spandau</investigator_affiliation>
    <investigator_full_name>Dr. Hanna Petersen</investigator_full_name>
    <investigator_title>Head of Institute for Pediatric Nutritional Research at the Waldkrankenhaus Protestant Hospital</investigator_title>
  </responsible_party>
  <keyword>galactagogue</keyword>
  <keyword>milk thistle</keyword>
  <keyword>silymarin</keyword>
  <keyword>Silitidil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Lactation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

